Physician profile
Michael Stuart Sweet
NPI 1598765786
$1,880.67
in general payments reported to CMS, 2019-2025
14 companies · $89.54 in 2025
The $89.54 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $219 · 2022: $100 · 2023: $324 · 2024: $1,147 · 2025: $89.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $431.20 | 2022-2024 | Farxiga, Airsupra, Lokelma |
| Kestra Medical Technology Services, INC. | $257.47 | 2024 | Assure Wcd |
| Boston Scientific Corporation | $212.82 | 2023-2024 | Watchman Flx, Watchman Access System |
| Janssen Scientific Affairs, LLC | $121.41 | 2024 | Tremfya |
| Sanofi-Aventis U.S. LLC | $106.13 | 2024 | |
| Scpharmaceuticals INC. | $106.00 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.81 | 2021 | |
| Cvrx, INC. | $94.57 | 2024 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $89.97 | 2021 | |
| Phathom Pharmaceuticals, INC. | $89.54 | 2025 | Voquezna |
| Medtronic, INC. | $88.75 | 2024 | Cobalt Dr Mri Surescan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.88 | 2024 | Lifevest |
| Lilly USA, LLC | $65.58 | 2024 | Mounjaro |
| Philips North America LLC | $29.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sweet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.